| New generation antipsychotic drugs using in the treatment for psychiatric patients have been reported to induce weight gain leading to overweight and metabolic syndrome.Objective= The purposes of this study were to determine the prevalence of weight gain in schizophrenia patients receiving Risperidone, Clozapine, Olanzapine or Quetiapine and to assess factors associated with weight gain in these patients. Methods= A cross-sectional study was performed in schizophrenia patients receiving risperidone, clozapine, olanzapine or at out-patient department of PrasrrimahabhodiPsychiatric Hospital, Ubonratchathanin July to September 2013. Data were collected using patient profiles and OPD cards. Baseline weight together with weight at 4, 8 and 12 weeks after antipsychotic drug initiation were recorded. The assessment of significant weight gain (≥7% increase versus baseline) according to FDA was used in this study. The descriptive statistic, chi-squared test, ANOVA and paired t-test were used to analyze the obtaining data. Results= There were 206 schizophrenic patients included in this study. Of those there were 113 male and 93 female. There were 134 subjects (65.0%) on risperidone, 56 subjects (27.2%) on clozapine, 8 subjects (3.9%) on olanzapine and 8 (3.9%) subjects on quetiapine. It was found that prevalence of weight gain at 4 week in patients receiving risperidone, clozapine, olanzapine and quetiapine were 24.5, 31.4, 33.3 and 0, respectively. After 8 week follow up, the prevalence of weight gain was 22.8, 33.3, 33.3 and 12.5, respectively. After 12 weeks, the prevalence of weight gain was 28.2, 46.2, 40.0 and 0, respectively. In comparison, mean weight change after using antipsychotic drugs for 4 weeks and baseline was found at 1.9, 2.8, 3.5and2.0 Kg. for risperidone, clozapine, olanzapine and quetiapine, respectively. These was not significantly different (p value = 0.353). After 8 weeks, mean weight increase was not different and were 1.6, 3.2, 2.7 and 1.1 respectively (p value = 0.164). After 12 weeks, mean weight increase were as follows= 1.8, 4.5, 4.2 and 1.5 respectively. Of those, the result revealed that weight gain from risperidone and clozapine was significantly different (p-value =0.007). In addition, it was found that age and occupation were associated with weight gain in patients receiving risperidone (p-value <0.05). Conclusion= The highest prevalence of patient with weight gain at 12 weeks was clozapine followed by olanzapine and risperidone. However, patients using quetiapine showed no significant weight gain. In addition, mean weight gain at 12 weeks comparing to baseline was highly found in clozapine following by olanzapine, risperidone and quetiapine. |